Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

STATUS

Recruiting
End date

May 15, 2025
participants needed

20
sponsor

University of Washington

Send

Updated on 12 May 2022

See if I qualify

ct scan

gonadotropin

cancer

absolute neutrophil count

androgens

gilbert's syndrome

glomerular filtration rate

testosterone

metastasis

neutrophil count

carboplatin

tumor cells

biomarker analysis

docetaxel

antiandrogen therapy

androgen suppression

bone scan

abiraterone

bone disease

orchiectomy

enzalutamide

serum testosterone

androgen

adenocarcinoma

parp inhibitor

lhrh analogue

palb2

adenocarcinoma of the prostate

sipuleucel-t

adenocarcinoma of prostate

Summary

This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.

Description

PRIMARY OBJECTIVES:

I. To determine radiographic progression free survival with 4 cycles of docetaxel with carboplatin followed by maintenance rucaparib camsylate (rucaparib) in the treatment of patients with metastatic castration resistant prostate cancer with homologous recombination DNA repair deficiency.

SECONDARY OBJECTIVES:

I. To assess maximal prostate-specific antigen (PSA) response to induction docetaxel and carboplatin.

II. To assess PSA response to switch maintenance with rucaparib. III. To assess PSA response duration to docetaxel and carboplatin followed by switch maintenance with rucaparib.

IV. To assess time to PSA progression with induction docetaxel and carboplatin followed by maintenance with rucaparib.

V. To assess response of measurable disease.

OUTLINE

INDUCTION: Patients receive docetaxel intravenously (IV) and carboplatin IV on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive rucaparib camsylate orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

Details

Condition	ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Treatment	laboratory biomarker analysis, docetaxel, carboplatin, rucaparib, Rucaparib Camsylate
Clinical Study Identifier	NCT03442556
Sponsor	University of Washington
Last Modified on	12 May 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Signed informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information
	Histologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)
	Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy; patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy
	Castration resistant prostate cancer as defined by serum testosterone < 50 ng/ml and PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart
	Presence of metastatic disease on bone or computed tomography (CT) scan
	Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
	Bone disease on bone scan
	Prior therapy with sipuleucel-T, abiraterone, enzalutamide, docetaxel, and/or
	cabazitaxel; there is no limit to the number of prior treatment regimens in
	Eastern Cooperative Oncology Group (ECOG) performance status of =< 1
	Life expectancy >= 12 weeks
	the castration resistant setting, so long as prior therapy does not include
	No prior malignancy is allowed except
	platinum chemotherapy or a PARP inhibitor; prior platinum chemotherapy in the
	hormone sensitive setting is permitted, so long as it has been at least 6
	Adequately treated basal cell or squamous cell skin cancer or
	In situ carcinoma of any site or
	months since last dose
	Other adequately treated malignancy for which the patient has been disease-free for at least one year (any prior chemotherapy is allowed)
	Documented evidence of at least ONE or MORE of the following
	Pathogenic mutation or inactivating alteration of a gene involved in homologous recombination repair in the tumor
	Note, that if this alteration is identified in a circulating tumor deoxyribonucleic acid (ctDNA) assay, the variant-allele fraction must be > 20% to indicate relevance to predominant tumor clone
	Mutation in one or more other genes involved in homologous DNA recombination repair in the tumor may be included at investigator's discretion
	Homologous recombination repair deficiency by genomic signature in the tumor by BROCA-HR, Foundation One or equivalent assay
	Presence of pathogenic or likely pathogenic germline mutation/variant in BRCA2, BRCA1, ATM or PALB2
	Platelets > 100 x 10^9/L (within 14 days of first dose of study drug)
	Hemoglobin >= 9 g/dL (within 14 days of first dose of study drug)
	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; if liver metastases, then =< 5 x ULN (within 14 days of first dose of study drug)
	Note: Germline mutations in other HR genes will be considered at investigator's
	Bilirubin =< 1.5 x ULN (< 2 x ULN if hyperbilirubinemia is due to Gilbert's syndrome) (within 14 days of first dose of study drug)
	discretion)
	Serum creatinine =< 1.5 x ULN or estimated glomerular filtration rate (GFR) >= 45 mL/min using the Cockcroft Gault formula (within 14 days of first dose of study drug)
	Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (within 14 days of first dose of study
	drug)
Exclusion Criteria
	Currently receiving active therapy for other neoplastic disorders
	Symptomatic and/or untreated central nervous system (CNS) metastases; patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks
	Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, active or symptomatic viral hepatitis or chronic liver disease
	Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline
	Treatment with an investigational therapeutic drug within 30 days of cycle 1
	Prior therapy with a PARP inhibitor (e.g., olaparib, talazoparib, veliparib, niraparib, rucaparib)
	Prior therapy with a platinum chemotherapy (e.g. cisplatin, carboplatin, oxaliplatin) in the castration resistant setting; (prior platinum chemotherapy in the hormone sensitive setting is permitted, so long as time since last dose is 6 months or greater)
	Active, ongoing toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade 2 or higher) from prior therapy
	Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding and/or giving of informed consent
	Pre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib
	Any condition(s), medical or otherwise, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ct scan

gonadotropin

cancer

absolute neutrophil count

androgens

gilbert's syndrome

glomerular filtration rate

adenocarcinoma of the prostate

sipuleucel-t

adenocarcinoma of prostate

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency